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Background. Intermittent application of chemotherapy and tyrosine kinase inhibitors may avoid antagonism between the two
classes of drugs. This hypothesis was tested in a Phase II clinical trial. Patients and Methods. Eligible patients were nonsmokers or
light smokers, chemo-na¨ ıve, with metastatic adenocarcinoma of the lung. Treatment: 4 to 6 cycles of gemcitabine 1250mg/m2 on
days 1 and 4, cisplatin 75mg/m2 on day 2, and erlotnib 150mg daily on days 5–15, followed by erlotinib as maintenance. Results.
24 patients entered the trial. Four pts had grade 3 toxicity. Complete remission (CR) and partial remission (PR) were seen in 5pts
and 9pts, respectively (response rate 58%). Median time to progression (TTP) was 13.4 months and median overall survival (OS)
was 23 months. When compared to patients with negative or unknown status of EGFR mutations, 8 patients with EGFR gene
activating mutations had signiﬁcantly superior experience: 4 CR and 4 PR, with median TTP 21.5 months and OS 24.2 months
(P<. 05). Conclusions. Intermittent schedule with gemcitabine, cisplatin and erlotinib has mild toxicity. For patients who are
positive for EGFR gene activating mutations, this treatment oﬀers excellent response rate, time to progression and survival.
1.Introduction
To the surprise and deep disappointment of all involved
in the treatment of lung cancer, several large trials did
not demonstrate any beneﬁt of tyrosine kinase inhibitors
(TKIs) as an addition to chemotherapy [1–3]. Virtually
all further clinical research on combinations of TKIs and
chemotherapy was then abandoned. Basic and clinical
research then focused on mutations of the gene for epider-
mal growth factor receptor (EGFR) as a predictive factor
for response to monotherapy with TKIs and to develop-
ment of new compounds with broader and/or irreversible
inhibition.
The biological basis for the negative experience with
combined treatment was never given proper attention.
Geﬁtinib and erlotinib met all three standard criteria for
inclusion in a combination with chemotherapy: activity as
monotherapy, diﬀerent mechanism of action, and diﬀerent
toxicity. Why, then, did the combination not work? As
explained in a recent editorial [4], we believe that the cells of
tumorssensitive toTKIsarepushedintotheG-0phaseofthe
cell cycle and therefore become resistant to cytotoxic drugs.
If antagonism between the two classes of drugs is really the
biological basis for the aforementioned negative experience,
then an optimal combination of TKIs and chemotherapy
should be in an intermittent, rather than a continuous
schedule.
This brief report presents a single-institution experience
on intermittent chemotherapy and TKI in a small series of
patients with advanced adenocarcinoma of the lung. Our
hypothesis was that intermittent treatment would lead to
superior time to progression, when compared to experience2 Journal of Biomedicine and Biotechnology
with chemotherapy alone. If conﬁrmed, such a result would
be a solid basis for a randomised clinical trial.
2. Patientsand Methods
2.1. Inclusion Criteria. Patients eligible for the trial were
chemona¨ ıve with microscopically conﬁrmed adenocarci-
noma of the lung, had stage III B (wet) or IV according
to UICC-TNM classiﬁcation (6th edition), had smoking
history of less than 10 packs in years, had an ECOG
performance status 0 or 1, and had adequate parameters of
hematological, liver, and renal function to receive cisplatin-
based chemotherapy. In the absence of neurological symp-
toms, patients with brain metastases were eligible and were
treated with brain irradiation only in case of intracranial
progression. All patients were fully informed and gave
written consent to participate in the trial.
2.2. Initial Diagnostics. All patients had their diagnosis
conﬁrmed by biopsy or cytology. At the time when the trial
was initiated, testing for EGFR mutations was not available.
Within three weeks prior to treatment, the precise extent
of the disease was determined by chest X-ray and CT
scanningofthechest,upperabdomen,andbrain.Since2008,
PET-CT scanning has been available and included in the
initial diagnostics and in followup.
2.3. Treatment. The treatment started with four cycles of
intermittent chemotherapy and erlotinib according to the
following schedule:
day 1: gemcitabine 1250mg/m2 in 30-minute infu-
sion,
day 2: cisplatin 75mg/m2, with appropriate hydra-
tion and antiemetics,
day 4: gemcitabine 1250mg/m2 in 30-minute infu-
sion,
days 5–15: erlotinib 150mg daily p.o.
Cycle was repeated on day 22.
Patients received 4 to 6 cycles of intermittent treatment.
The number of cycles depended on tolerance to cisplatin-
based chemotherapy and was determined individually.
Immediately after the last cycle, patients continued with
erlotinib 150mg/m2 daily continuously until progression or
unacceptable toxicity.
2.4. Monitoring for Response, Time of Progression, and Follow-
up. Deﬁnition of complete response (CR), partial response
(PR), stable disease (SD), and progression followed the
RECIST criteria [5].
The ﬁrst evaluation of response was done during the
third cycle of intermittent therapy, with conﬁrmation of
response during the ﬁfth cycle. After 4 cycles, patients were
seen every second month. Control radiological examinations
wererepeatedevery2monthsforchestX-ray,every4months
for CT, and at 6 and 12 months for PET-CT (only patients
who had this examination during their initial diagnostics).
2.5. Posttreatment Analysis of Archived Bioptic Material.
In October 2010, all biopsy samples were reviewed, and
specimens with more than 10% of tumour tissue were
analyzed. Genomic DNA was extracted from formalin-ﬁxed,
paraﬃn-embedded tissue sections using QIAAmp DNA
FFPE tissue kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. Quantiﬁcation of extracted
DNA was done on Qubit Fluorometer (Invitrogen, Carls-
bad, USA). To detect EGFR gene-activating mutations, we
used TheraScreen EGFR29 Mutation Kit (DxS Diagnostics,
Qiagen, Manchester, UK). All realtime PCR reactions were
performed in a 25μL ﬁnal volume on ABI 7500 instrument
(Applied Biosystems, Carlsbad, USA).
2.6. Endpoints and Statistical Planning. The primary end-
point was time to progression. Secondary endpoints were
response rate, toxicity, and overall survival.
After standard chemotherapy for metastatic nonsmall
cellcarcinoma,theexpectedTTPis5months.Thesizeofthis
single-arm nonrandomised trial of intermittent therapy was
based on the assumption of 9 months as the median time to
progression (TTP). To obtain such a result with a conﬁdence
interval of 6–12 months, we planned to recruit 40 patients.
2.7. Ethical Considerations. The investigators strictly fol-
lowed recommendations of the Helsinki Declaration (1964,
with later amendments) and of the European Council Con-
vention on Protection of Human Rights in Bio-Medicine,
as accepted in Oviedo in 1997. The protocol was approved
by the Institutional Review Board (Institute of Oncology,
Ljubljana) and by the National Committee for Medical
Ethics, Ministry of Health, Republic of Slovenia.
3. Results
3.1. Patient Population. Between September 2005 and July
2010, 25 patients were recruited into the trial. One patient
was later found to have metastatic carcinoma of the pancreas
rather than primary lung cancer and was excluded from all
further analyses.
With 12 patients each, male and female patients were
eq uall yr ep r ese nt ed.M edianagewas50y ears(range:25t o73
years). Twelve patients were never-smokers, and most were
in good general condition (PS 0-1 for 21 patients). With
the exception of a single patient with “wet” stage III B, all
other patients had stage IV disease. Bone metastases were
the most common site of metastatic disease, followed by
pleura/pericardium, contralateral lung metastases, and liver.
Two or more sites of metastatic disease were documented in
4 and 12 patients, respectively (Table 1).
3.2. Analysis of EGFR Mutations in Bioptic Material. Analysis
of the archived bioptic material was completed in October
2010.
Three patients had only cytological diagnosis, and an
additional 3 had biopsy samples too small to allow for anal-
ysis of EGFR mutations in tumor cells. Of the 18 adequate
samples,8werepositiveforEGFRgene-activatingmutations.Journal of Biomedicine and Biotechnology 3
(a) (b)
Figure 1: A woman, 39, never-smoker, developed adenocarcinoma of the right lower lobe, T4 N2 M1b with metastases in bone and liver.
18F-FDG PET-CT before treatment (a) and after 4 months (b). Complete remission was conﬁrmed also a year later.
(a) (b)
Figure 2: The same patient as on Figure 1. Bone metastasis in the right iliac bone (a) and complete response after treatment (b).
3.3. Treatment. The actual number of cycles of intermittent
therapy was from 1 to 6 cycles (median: 4 cycles). Due to
early progression, one patient did not receive erlotinib as
maintenancetreatment.InOctober2010,7patientswerestill
on maintenance treatment with erlotinib, and an additional
patient stopped treatment with erlotinib after 12 months
in PET-CT conﬁrmed complete remission (Figures 1 and
2). For the remaining patients, median total duration of
treatment was 10 months.
3.4. Toxicity. During the initial phase, 3pts had grade 3
toxicity (2 neutropenia, 1 thrombocytopenia). Side eﬀects of
maintenance with erlotinib were skin toxicity (grade 3: 1pt;
grade 2: 11pts) and diarrhea (grade 2 in 1pt).
No patient experienced grade 4 or greater toxicity.
3.5. Response to Treatment, Time to Progression, and Survival.
All patients are evaluable for response, and no patient has
been lost to followup. For the whole group of 24 patients,
complete remission (CR) was seen in 5 pts; partial remission
(PR) in 9pts (response rate 58%), minimal response or
stable disease (SD) in 8pts, and progression in 2pts. A
clear and statistically signiﬁcant (P<. 05) correlation was
seen between the presence of activating EGFR mutations
and response. Among the 8 patients who were positive for
EGFR gene-activating mutations, 4 complete and 4 partial
remissions were seen. On the other hand, no CR and only 2
PR were seen among the 10 patients negative for mutations
(Table 2).
For the whole group, median time to progression (TTP)
was 13.4 months, and median overall survival (OS) was 23
months. Again, patients positive for EGFR gene-activating
mutations had-superior experience. Median TTP and OS for
this group was 21.5 months and 24.2 months, respectively.
For patients without EGFR mutations, TTP was 5 months,
and OS was 7 months (Table 2 and Figures 3 and 4).
4. Discussion and Conclusions
Thisclinicaltrialwaslaunchedatatimewhenroutinetesting
for EGFR gene-activating mutations was not yet available.
Selection of patients for a combination of chemotherapy and
erlotinib was made on the basis of classical histopathology
(adenocarcinoma) and smoking status.
Recent developments led to premature closure of our
trial. Since testing for EGFR gene mutations is now available,4 Journal of Biomedicine and Biotechnology
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it is clear that patients with activating mutations are those
who really beneﬁt from TKIs. In addition, standard ﬁrst-
linetreatmentforpatientswithactivatingEGFRmutationsis
now monotherapy with a TKI [6, 7]. Since continuing a trial
with the same selection criteria and without considering the
status of EGFR gene activating mutations was not justiﬁed,
the research group made a decision to close the trial and
analyse the experience.
Inordertogetalongerintervalforintermittent erlotinib,
gemcitabine was given on days 1 and 4 of the cycle. When
compared to the standard day 1 and day 8 schedule, this
minor modiﬁcation in timing of cytotoxic drugs did not
have anyadverse eﬀecton thetolerancetotreatment. Clearly,
other platin-based schedules which apply chemotherapy on
a 3-weekly basis (such as pemetrexed-cisplatin or paclitaxel-
carboplatin) can oﬀer an even longer interval for TKIs
and might be considered for future trials of intermittent
treatment.
Two other groups recently reported promising experi-
ence with intermittent chemotherapy and TKIs. In a trial
from the USA, two schedules of intermittent treatment were
tested [6]. In combination with pemetrexed (500mg/m2 on
day 1), erlotinib was given either as a pulse application in
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Figure 4: Overall survival in relation to the status of EGFR gene
activating mutations
and 16, or in lower doses (150–250mg daily) on days 2
to 16. Patients had various advanced malignancies, most of
which were pretreated. While tolerance to this treatment
was good, the small number and heterogeneity of patients
recruited into this trial do not allow for any clear conclusion
regarding the eﬀectiveness of intermittent treatment. Of
more importance is a randomised Phase II trial by MokJournal of Biomedicine and Biotechnology 5
Table 2: Response to treatment, time to progression, and survival in relation to EGFR mutations.
EGFR mutations
Positive Negative Unknown All
Response to treatment
CR 4 — 1 5
PR 4 2 3 9
SD — 6 2 8
Progression — 2 — 2
Time to progression (months) Median (95% CI) 21.5 (14.8–27.2) 5.0 (0.9–9.1) 5.0 (3.9–4.1) 13.4 (5.4–20.6)
Survival (months) Median (95% CI) 24.2 7.0 (0.1–13.9) 11.0 23.0 (10.9–35.2)
et al. [7]. This study from Asia compared gemcitabine and
either cisplatin or carboplatin to a schedule with addition of
intermittentapplicationoferlotinib(150mgondays14to28
ofthecycle)andreportedsigniﬁcantlysuperiorTTPwiththe
intermittent schedule. Their experience is most valuable but
may not be of direct relevance for the rest of the world, due
to the well-known diﬀerences in sensitivity of lung cancer to
TKIs between Asian and Caucasian patients.
Despite its small size, our trial can oﬀer valuable experi-
ence for further research on optimisation of treatment with
combinations of chemotherapy and TKIs. Looking at the
whole series of patients, we can conclude that intermittent
chemotherapy and erlotinib is a treatment of very low
toxicity. It is also clear that the eﬃcacy of treatment is closely
related to the presence or absence of EGFR gene-activating
mutations.
The most important ﬁnding is the excellent response
rate with a substantial proportion of complete responses
and prolonged TTP and OS for patients positive for EGFR
gene-activating mutations. For many years, the maximal
expectation of a patient with metastatic nonsmall cell lung
cancer was a partial remission of relatively short duration in
the range of 5 to 9 months. With intermittent treatment, we
now see durable complete remissions in a subpopulation of
patients. While the number of patients in our trial is small
and any deﬁnitive conclusion would be premature, we nev-
ertheless believe that further research of intermittent therapy
for patients positive for EGFR gene-activating mutations is
warranted. A randomised trial comparing ﬁrst-line TKI as
monotherapy to the intermittent schedule should clarify the
real value of this new approach.
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